• Shashikant Vaidya Department of Clinical Pathology, Haffkine Institute for Training, Research and Testing, Mumbai, India
  • Vidushi Chitalia Department of Clinical Pathology, Haffkine Institute for Training, Research and Testing, Mumbai, India
  • Shreyasi Muley Haffkine Bio-pharmaceutical Corporation Ltd. Mumbai, India
  • Geeta Koppikar Breach Candy Hospital Trust, Mumbai, India
  • Mohan Kulkarni T.N. Medical College and B.Y.L. Nair Charitable Hospital, Mumbai, India
  • Abhay Chowdhary Grant Government Medical College and Sir JJ Hospital, Mumbai, India





Mycobacteria other than Mycobacterium tuberculosis (MOTT) cause infections more commonly in the presence of predisposing factors and underlying diseases.They are also notably resistant to commonly used antituberculosis drugs. Total 11 clinical isolates MOTT were included in the study.Drug susceptibility testing of these isolates was performed by Resistant Ratio method. Minimum inhibitory concentration (MIC) pattern of these isolates of MOTT to mycelia acid synthesis inhibitors namely, Isoxyl(ISO) and Isoniazid (INH) were determined by agar dilution and broth dilution method. Minimum bactericidal concentration (MBC) pattern of these isolates to ISO and INH werealso determined. Out of 11 MOTT isolates, 3 isolates were characterized as Mycobacteriumscrofulaceum, 3 isolates as Mycobacteriumfortuitum, 2 isolates as Mycobacteriumflavescens, 1 isolates as Mycobacterium terrae and 2 isolates as Mycobacteriumkansasi depending upon the results of biochemical tests.The MBC range of INH was found to be 0.025 to 6.4 μg/ml and of ISO was found to be 0.6 to 20 μg/ml. Bactericidal activity of ISO was 7.25 times lower than the activity of INH. It is well known that most MOTT species are more resistant to chemotherapeutic agents other than tubercle bacilli.The inhibitory activity of ISO was more to MOTT strains than Mycobacterium tuberculosis strains.There was low bactericidal activity of ISO to MOTT strains, but better than for Mycobacterium tuberculosis strains. 


Bates, J. H. (2012). Tuberculosis chemotherapy. The need for new antituberculosis drugs is urgent. American journal of respiratory and critical care medicine. 151:942 .

Cannetti, G. S., Froman, J., Grosset, P., Hauduroy, M., Langerora, H.T., Mahler, G., Meissner, Mitchison, D.A. and Sula, L. (1963). Mycobacteria: Laboratory methods for testing drug sensitivity and resistance. Bull W.H.O., 29, 565-578.

Chakrabarti, A., Sharma, M., & Dubey, M. (1990). Isolation rates of different mycobacterial species from Chandigarh (north India). The Indian journal of medical research, 91, 111-114.

Cruikshank, R., Duguid, J.P., Swain, R.H.A. (1968). Medical Microbiology (Vol. 53).Edinburgh and London: The ELBS and ES Livingstone Ltd.

David, H. L., Rastogi, N., Clavel-Sérès, S., & Clément, F. (1988). Alterations in the outer wall architecture caused by the inhibition of mycoside C biosynthesis inMycobacterium avium. Current microbiology, 17(2), 61-68.

Dharmshala, S., Jangale, N., Patil, S., Gohil, A. and Chowdhary, A. (2005). Evaluation of drug resistance pattern in M. tuberculosis and non tuberculous Mycobacteria. Abstract book. National consultation on drug resistance in Malaria, TB and HIV/AIDs.

Hawkins, J. E., Wallace Jr, R. J., & Brown, B. A. (1991). Antibacterial susceptibility tests: Mycobacteria. Non-weekend schedule for BACTEC susceptibility testing of Mycobacterium tuberculosis. J. Clin. Microbiol. 23:934-937

Heifets, L. B. (1991). Drug susceptibility in the chemotherapy of mycobacterial infections: CRC press.

Jesudason, M., & Gladstone, P. (2005). Non tuberculous mycobacteria isolated from clinical specimens at a tertiary care hospital in South India. Indian journal of medical microbiology, 23(3), 172.

Karak, K., Bhattacharyya, S., Majumdar, S., & De, P. (1996). Pulmonary infection caused by mycobacteria other than M. tuberculosis in and around Calcutta. Indian Journal of Pathology and Microbiology, 39(2), 131-134.

Katoch, V. (2004). Infections due to non-tuberculous mycobacteria (NTM). Indian Journal of Medical Research, 120, 290-304.

Matlola, N., Steel, H., & Anderson, R. (2001). Antimycobacterial action of B4128, a novel tetramethylpiperidyl-substituted phenazine. Journal of Antimicrobial Chemotherapy, 47(2), 199-202.

Phetsuksiri, B., Baulard, A. R., Cooper, A. M., Minnikin, D. E., Douglas, J. D., Besra, G. S., & Brennan, P. J. (1999). Antimycobacterial activities of isoxyl and new derivatives through the inhibition of mycolic acid synthesis. Antimicrobial agents and chemotherapy, 43(5), 1042-1051.

Reddy, V. M., Nadadhur, G., Daneluzzi, D., Dimora, V. and Gangadharam, P.R.J. (1995). Antimycobacterial activity of new Rifamycin derivative 3-(4-cinnamylpiperazinyl Iminomethyl Rifamycin SV (T9). Antimicrob Agents Chemother, 39(10), 2320-2324.

Rosenzweig, D. Y. (1979). Pulmonary mycobacterial infections due to Mycobacterium intracellulare-avium complex. Clinical features and course in 100 consecutive cases. CHEST Journal, 75(2), 115-119.

Schmid, C. (1970). Clinical experience in cases of primary tuberculosis with tuberculostaticum isixyl. Antibiot Chemother, 16, 108-116.

Tacquet, A., Devulder, B., Tison, F., & Martin, J. (1970). Activité de l’Isoxyl sur Mycobacterium kansasii; Etudes in vitro et chez le cobaye pneumoconiotique.Inst. Pasteur Lille.10: 43.

Titscher, R. (1966). Monotherapie mit isoxyl/DAT bei tuberculose-asylierungsfallen. Prax. Pneumol, 20, 202-206.

Tomioka, H., Saito, H., Fujii, K., Sato, K., & Hidaka, T. (1993). In vitro antimicrobial activity of benzoxazinorifamycin, KRM-1648, against Mycobacterium avium complex, determined by the radiometric method. Antimicrobial agents and chemotherapy, 37(1), 67-70.

Tsukamura, M., Kita, N., Shimoide, H., Arakawa, H., & Kuze, A. (1988). Mycobacteriosis in Japan1. 2. Am Rev Respir Dis, 137, 1280-1284.

Urbancik, B. (1970). Clinical experiences with thiocarlide ( Isoxyl). Antibiot Chemother, 16, 117-123.

Winder, F. G. (1982). Mode of action of the antimycobacterial agents and associated aspects of the molecular biology of the mycobacteria. The biology of the mycobacteria, 1, 353-438.

Winn, W. C., & Koneman, E. W. (2006). Koneman's color atlas and textbook of diagnostic microbiology: Lippincott williams & wilkins.

Wolinsky, E. (1979). Nontuberculous Mycobacteria and Associated Diseases 1, 2. American Review of Respiratory Disease, 119(1), 107-159.

Yates, M., & Collins, C. (1981). Sensitivity of opportunist mycobacteria to rifampicin and ethambutol. Tubercle, 62(2), 117-121.




How to Cite

Vaidya, S., Chitalia, V., Muley, S., Koppikar, G., Kulkarni, M., & Chowdhary, A. (2015). DETERMINING THE EFFICACY OF ISOXYL, A MYCOLIC ACID INHIBITOR, IN VITRO AGAINST MYCOBACTERIA OTHER THAN MYCOBACTERIUM TUBERCULOSIS (MOTT) STRAINS. LIFE: International Journal of Health and Life-Sciences, 1(01), 90–107.

Most read articles by the same author(s)